Cardiovascular benefits have been demonstrated in clinical trials for specific GLP-1 receptor agonists, with liraglutide, semaglutide, and dulaglutide showing reductions in major adverse cardiovascular events in patients with established cardiovascular disease or high cardiovascular risk
doi: 10.1016/j.jagp.2023.08.010 [DOI] [PubMed] [Google Scholar] 82.Tang H, Lu Y, Donahoo WT, et al
Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice
Its HIPAA-compliant patient-level data capabilities allow for precise audience targeting based on clinical, behavioral, and prescription insights
Obesity management is emerging as the fastest-growing application
This is the most dangerous timing mistake you can make